Literature DB >> 9847685

[Cirrhosis of the liver as a precancerous condition].

K P Maier1.   

Abstract

Cirrhosis of the liver can be regarded as premalignant state, since more than 80 percent of hepatocellular carcinoma (HCC) in the western world develop in a cirrhotic liver. The risk to develop this malignancy depends on the activity of the underlying cirrhosis, its etiology and the duration of the disease. Patients suffering from cirrhosis of the liver due to HBV-, HCV- or HDV-infection and patients with genetic hemochromatosis exhibit a high risk for HCC. This risk is further increased by cocarcinogens, such as alcohol, nicotine and toxins. Ultrasound and AFP-studies aim to diagnose HCC early. The sensitivity of AFP in the serum is remarkably low (about 64%). In contrast a normal AFP-concentration (< 20 ng/ml) carries a high negative prognostic value (> 90%). Patients suspected to suffer from HCC according to the results of screening procedures should be subjected to additional radiologic investigations, such as CT-arterioportography or lipiodol-angiography.

Entities:  

Mesh:

Year:  1998        PMID: 9847685

Source DB:  PubMed          Journal:  Praxis (Bern 1994)        ISSN: 1661-8157


  3 in total

Review 1.  Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation.

Authors:  Yewei Liu; Shuncong Wang; Xiaohui Zhao; Yuanbo Feng; Guy Bormans; Johan Swinnen; Raymond Oyen; Gang Huang; Yicheng Ni; Yue Li
Journal:  Diagnostics (Basel)       Date:  2020-01-31

2.  Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P.

Authors:  Yewei Liu; Ting Yin; Frederik De Keyzer; Yuanbo Feng; Feng Chen; Jianjun Liu; Shaoli Song; Jie Yu; Vincent Vandecaveye; Johan Swinnen; Guy Bormans; Uwe Himmelreich; Raymond Oyen; Jian Zhang; Gang Huang; Yicheng Ni
Journal:  Oncotarget       Date:  2017-07-18

3.  Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.

Authors:  Ye-Wei Liu; Frederik De Keyzer; Yuan-Bo Feng; Feng Chen; Shao-Li Song; Johan Swinnen; Guy Bormans; Raymond Oyen; Gang Huang; Yi-Cheng Ni
Journal:  World J Gastroenterol       Date:  2018-07-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.